28.92

3.47% -1.04

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $28.92, with a volume of 811.73K. It is down -3.47% in the last 24 hours and up +30.74% over the past month. Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Previous Close:

$29.96

Open:

$29.79

24h Volume:

811.73K

Relative Volume:

0.63

Market Cap:

$3.64B

Revenue:

$236.00M

Net Income/Loss:

$-369.00M

P/E Ratio:

-9.0863

EPS:

-3.1828

Net Cash Flow:

$-489.00M

1W Performance:

-4.65%

1M Performance:

+30.74%

6M Performance:

+37.65%

1Y Performance:

+203.14%

1-Day Range:

$28.13

$29.79

1-Week Range:

$28.13

$31.23

52-Week Range:

$8.84

$31.73

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

601

Twitter

@arcusbio

Next Earnings Date

2026-08-05

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	28.92	3.64B	236.00M	-369.00M	-489.00M	-3.1828
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-13-26	Upgrade	Goldman	Neutral → Buy
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Jul 09, 2026

Form 144 Arcus Biosciences For: 9 July By Investing.com - Investing.com Nigeria

Jul 09, 2026

Trust files proposed RCUS Class A sales (RCUS) — multiple dates and amounts - Stock Titan

Jul 09, 2026

Arcus Biosciences awards stock options to five new employees - Stock Titan

Jul 09, 2026

(RCUS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jul 09, 2026

Jul 07, 2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer - AOL.com

Jul 07, 2026

Arcus Biosciences Announces New Employment Inducement Grants - AOL.com

Jul 07, 2026

Jul 05, 2026

Arcus Biosciences (RCUS) Surges 4.88% as Shares Test Key Resistance LevelThematic ETF Flow - dars.gov.et

Jul 05, 2026

Arcus Biosciences (RCUS) Gains Fresh Attention As Nature Study Puts Valuation Back In Focus - Sahm

Jul 05, 2026

Jul 04, 2026

How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data - Sahm

Jul 04, 2026

Jul 01, 2026

Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination - Yahoo Finance

Jul 01, 2026

RCUSArcus Biosciences Inc Latest SEC Filings - Finviz

Jul 01, 2026

Arcus kidney cancer drug shows 12.2-month median survival By Investing.com - Investing.com Nigeria

Jul 01, 2026

HIF-2a inhibition with casdatifan (IMAGE) - EurekAlert!

Jul 01, 2026

Arcus Biosciences (RCUS) Unveils Promising ARC-20 Study Findings on Casdatifan - GuruFocus

Jul 01, 2026

Arcus kidney cancer drug shows 12.2-month median survival - Investing.com

Jul 01, 2026

New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan - EurekAlert!

Jul 01, 2026

Jun 29, 2026